News -

Maximising Drug Discovery Research- Interview with Attana CEO, Teodor Aastrup

"Drug discovery scientists should focus on the biological relevance of their candidate molecules as soon as possible in their research, to ensure a high probability of success in later stages”, says Teodor Aastrup, Chief Executive Officer and Founder of Attana AB. To maximise productivity, there is a need to understand reactions and interactions in the human body before research has advanced too much."

Click here to read the entire interview or access the pdf attached below.

Related links

Topics

  • Medical research

Categories

  • drug discovery
  • attana
  • marcus evans
  • discovery summit 2011
  • biosensor
  • attana cell 200

Contacts

Related content

  • Fight against cancer - Attana's collaborator interviewed

    Attana's collaborator at Gothenburg University, Dr. Sture Lindegren, is interviewed about a possible new cure for ovarian cancers. Using the Attana Cell 200 instrument, Dr. Lindegren and his team are testing antibodies as carriers of radionuclide that target cancer cells directly instead of affecting the whole body as current cancer therapies do.

  • Attana's Story told by CEO and co-founder Dr. Teodor Aastrup

    When we founded Attana in 2002, we had a dream of creating a tool that could mimic reality. We were set to do this by developing an instrument capable of measuring biological interactions exactly as the actual events in the human body.

Related events